KNSA:NSD-Kiniksa Pharmaceuticals Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 22.99

Change

-0.05 (-0.22)%

Market Cap

USD 1.59B

Volume

0.43M

Analyst Target

USD 37.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.07 (+0.54%)

USD 13.87B
NBIX Neurocrine Biosciences Inc

-1.50 (-1.18%)

USD 12.37B
ITCI Intracellular Th

-0.27 (-0.31%)

USD 9.17B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
HCM HUTCHMED DRC

-0.44 (-2.52%)

USD 3.18B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
SUPN Supernus Pharmaceuticals Inc

-0.06 (-0.16%)

USD 1.93B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B

ETFs Containing KNSA

IEEM:LSE iShares MSCI Emerging Mar.. 0.00 % 0.00 %

-10.13 (-1.08%)

N/A
IQQE:F iShares MSCI EM UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
IEEM:SW iShares MSCI EM UCITS ETF.. 0.00 % 0.00 %

-0.46 (-1.08%)

USD 4.91B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.07% 83% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.07% 82% B 80% B-
Trailing 12 Months  
Capital Gain 44.14% 79% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.14% 76% C+ 78% C+
Trailing 5 Years  
Capital Gain 256.43% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 256.43% 93% A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 12.63% 58% F 66% D+
Dividend Return 12.63% 58% F 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.19% 67% D+ 48% F
Risk Adjusted Return 32.22% 79% B- 64% D
Market Capitalization 1.59B 85% B 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.